A growing body of work implicates chemokines and their receptors in the progression of various types of cancer, including breast cancer. However, as potent chemotactic factors for leukocytes, chemokines also have the potential to enhance anti-cancer immunity. Evidence suggests that the chemokine CXCL12 and its receptors may be important in a number of aspects of breast cancer progression and site-specific metastasis. Another chemokine, CXCL16, has been identified as a specific chemotactic factor for Type Ipolarised T lymphocytes, which are major effectors of cell-mediated immunity and hence efficacious anti-tumour immune responses. The aim of this study, therefore, was to further elucidate the roles of CXCL12 and CXCL16 in breast cancer development and metastasis. To achieve this, wild-type CXCL12 and CXCL16 and antagonists of CXCL12 and CXCL16 activity, CXCL12[subscript](P2G) and CXCL16[subscript](9-220) respectively, were overexpressed in the 4T1.2 mouse model of breast carcinoma. Overexpression of wild-type CXCL12 potently inhibited both primary tumour growth and metastasis in this model. This was attributed to the induction of an anti-tumour response dependent, in part, on T cells, interferon-g and the cytotoxic mediators perforin and TRAIL. This response was characterised by increased numbers of CD11c⁺ cells in the tumour-draining lymph nodes and enhanced cytolytic activity of lymph node-derived effector cells against tumour cells. Unexpectedly, CXCL12[subscript](P2G) inhibited metastasis of tumour cells to the lungs of tumour-bearing mice, without affecting primary tumour growth. Intravenous injection of tumour cells revealed that CXCL12[subscript](P2G) expression could block metastatic steps occurring post tumour cell escape from the primary tumour, though a role for CXCL12([subscript](P2G) at earlier metastatic steps could not be ruled out. Further work is needed to clarify the precise stages of metastasis at which CXCL12[subscript](P2G) exerts its effects. No obvious effects on primary breast tumour growth were observed when CXCL16 or CXCL16([subscript](9-220) were overexpressed in tumour cells. Interestingly, CXCL16[subscript](9-220) expression inhibited experimental metastasis but not spontaneous metastasis. The findings of this study begin to shed light on the roles of CXCL12 and CXCL16 in breast cancer progression and also highlight the potential therapeutic applications of CXCL12, CXCL16 and/or their antagonists in the treatment of breast cancer and breast cancer metastasis. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1297662 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2007

Thesis (M.S.)--Brigham Young University. Dept. of Microbiology and Molecular Biology, 2008. / Includes bibliographical references (p. 44-47).

Thesis (Ph. D. in Molecular Physiology and Biophysics)--Vanderbilt University, Dec. 2009. / Title from title screen. Includes bibliographical references.

No description available.

A growing body of work implicates chemokines and their receptors in the progression of various types of cancer, including breast cancer. However, as potent chemotactic factors for leukocytes, chemokines also have the potential to enhance anti-cancer immunity. Evidence suggests that the chemokine CXCL12 and its receptors may be important in a number of aspects of breast cancer progression and site-specific metastasis. Another chemokine, CXCL16, has been identified as a specific chemotactic factor for Type Ipolarised T lymphocytes, which are major effectors of cell-mediated immunity and hence efficacious anti-tumour immune responses. The aim of this study, therefore, was to further elucidate the roles of CXCL12 and CXCL16 in breast cancer development and metastasis. To achieve this, wild-type CXCL12 and CXCL16 and antagonists of CXCL12 and CXCL16 activity, CXCL12[subscript](P2G) and CXCL16[subscript](9-220) respectively, were overexpressed in the 4T1.2 mouse model of breast carcinoma. Overexpression of wild-type CXCL12 potently inhibited both primary tumour growth and metastasis in this model. This was attributed to the induction of an anti-tumour response dependent, in part, on T cells, interferon-g and the cytotoxic mediators perforin and TRAIL. This response was characterised by increased numbers of CD11c⁺ cells in the tumour-draining lymph nodes and enhanced cytolytic activity of lymph node-derived effector cells against tumour cells. Unexpectedly, CXCL12[subscript](P2G) inhibited metastasis of tumour cells to the lungs of tumour-bearing mice, without affecting primary tumour growth. Intravenous injection of tumour cells revealed that CXCL12[subscript](P2G) expression could block metastatic steps occurring post tumour cell escape from the primary tumour, though a role for CXCL12([subscript](P2G) at earlier metastatic steps could not be ruled out. Further work is needed to clarify the precise stages of metastasis at which CXCL12[subscript](P2G) exerts its effects. No obvious effects on primary breast tumour growth were observed when CXCL16 or CXCL16([subscript](9-220) were overexpressed in tumour cells. Interestingly, CXCL16[subscript](9-220) expression inhibited experimental metastasis but not spontaneous metastasis. The findings of this study begin to shed light on the roles of CXCL12 and CXCL16 in breast cancer progression and also highlight the potential therapeutic applications of CXCL12, CXCL16 and/or their antagonists in the treatment of breast cancer and breast cancer metastasis. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1297662 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2007

Thesis (Ph. D.)--Virginia Commonwealth University, 2009. / Prepared for: Dept. of Biochemistry. Bibliography: leaves 147-171. Also available on the Internet.

Thesis (M. Phil.)--University of Hong Kong, 2006. / Title proper from title frame. Also available in printed format.

Background: Asthma is characterized by chronic airway inflammation in which leukocytes are attracted into the inflamed airway under the influence of chemokines. Molecular studies and allergen bronchoprovocation suggested that chemokines such as thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC), eotaxin and regulated upon activation normal T-cell expressed and secreted (RANTES) were involved in the airway responses to allergen exposure. / Conclusions: Chemokines are important mediators in the pathophysiology of asthma and atopy. TARC in plasma and MDC in EBC appear to be useful biomarkers for assessing childhood asthma. Besides, MDC concentrations in UCB may predict the susceptibility to develop wheezing during infancy. / Methods: Asthmatic patients, non-allergic controls and healthy singleton newborns were recruited from attendants of a university teaching hospital. Atopy-related chemokines in peripheral blood and EBC were measured by enzyme-linked immunosorbent assays. Genomic DNA from asthmatics and controls was genotyped by restriction fragment length polymorphism to characterize single nucleotide polymorphisms (SNPs) in the genes encoding TARC, RANTES, interleukin-13 and CD14. / Objectives: This thesis investigated the relation between chemokines and asthma and atopy by: (a) measuring their concentrations in peripheral blood and exhaled breath condensate (EBC); (b) performing case-control association studies for genes encoding atopy-related chemokines and related molecules; and (c) analyzing chemokines in umbilical cord blood (UCB) in relation to wheezing phenotypes during infancy. / Results: Plasma TARC concentrations were higher in children with chronic asthma than controls, and also correlated with plasma total IgE. Among children with asthmatic exacerbation, plasma TARC concentrations showed inverse correlation with peak expiratory flow rates at presentation. When measured in EBC, MDC but not TARC or eotaxin was higher in asthmatics than controls. In our genetic association studies, SNPs in IL13, RANTES and TARC were associated with serum total and/or allergen-specific IgE. TARC C-431T was also linked to peripheral eosinophilia. However, none of these polymorphisms was associated with physician-diagnosed asthma. Interestingly, C-159T in CD14 was also associated with serum total IgE, but only among atopic asthmatic children. In the last part involving 124 singleton healthy newborns, MDC concentrations in UCB were significantly increased in newborns who wheezed during infancy. / Leung Ting-fan. / Adviser: Gary W.K. Wong. / Source: Dissertation Abstracts International, Volume: 73-01, Section: B, page: . / Thesis (M.D.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 196-231). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web.

published_or_final_version / abstract / Paediatrics and Adolescent Medicine / Master / Master of Philosophy

published_or_final_version / Surgery / Doctoral / Doctor of Philosophy